The present invention relates to a porous scaffold having excellent tissue engineering properties, and a method for manufacturing same. The scaffold of the present invention can be manufactured by a simple process, and exhibits high tensile strength and biocompatibility, as well as an excellent cell engraftment rate, and thus can be useful as a support composition for various of human transplantation, for example, as a support for artificial ligaments or abdominal wall reinforcement.

An object of the present invention is to provide a composition capable of realizing an excellent matt tone of a leather surface in a case of being used as a synthetic leather or an artificial leather, a sheet-shaped molded body, an artificial leather, and a manufacturing method of a sheet-shaped molded body. The composition of the present invention is a composition used for a synthetic leather or an artificial leather, the composition containing a polypeptide, a fibrous substance other than the polypeptide, and, a plasticizer.

An object of the present invention is to provide a composition capable of realizing an excellent matt tone of a leather surface in a case of being used as a synthetic leather or an artificial leather, a sheet-shaped molded body, an artificial leather, and a manufacturing method of a sheet-shaped molded body. The composition of the present invention is a composition used for a synthetic leather or an artificial leather, the composition containing a polypeptide, a fibrous substance other than the polypeptide, and, a plasticizer.

An injectable in situ pore-forming hydrogel system and its preparation method and use are provided. The injectable in situ pore-forming hydrogel system uses an injectable hydrogel as a continuous base phase, and isolated live cells and magnesium particles are distributed in the continuous base phase, where the injectable hydrogel is a precursor or prepolymer of hydrogel, which can form hydrogel by cross-linking. The injectable in situ pore-forming hydrogel system can be used to create pores while the gel encapsulates live cells, which makes use of both the injectability and porous structures of hydrogel, which is important for the repair of cavitary, surgically difficult and irregularly defective tissues; meanwhile, magnesium particles generate magnesium ions after the former undergoes gas production and degradation, which can improve the bioactivity of the gel and aid in tissue repair.

An injectable in situ pore-forming hydrogel system and its preparation method and use are provided. The injectable in situ pore-forming hydrogel system uses an injectable hydrogel as a continuous base phase, and isolated live cells and magnesium particles are distributed in the continuous base phase, where the injectable hydrogel is a precursor or prepolymer of hydrogel, which can form hydrogel by cross-linking. The injectable in situ pore-forming hydrogel system can be used to create pores while the gel encapsulates live cells, which makes use of both the injectability and porous structures of hydrogel, which is important for the repair of cavitary, surgically difficult and irregularly defective tissues; meanwhile, magnesium particles generate magnesium ions after the former undergoes gas production and degradation, which can improve the bioactivity of the gel and aid in tissue repair.

The present invention relates to a novel acellular artificial skin substitute or scaffolds comprising biopolymer and bioactive components and the process of preparing said artificial skin substitute. The novel artificial foam-based skin substitute scaffold of the present invention addresses the problems in the prior art by providing a biocompatible, biodegradable, Non-immunogenic, non-irritant and a cost-effective scaffold.

The present invention relates to a novel acellular artificial skin substitute or scaffolds comprising biopolymer and bioactive components and the process of preparing said artificial skin substitute. The novel artificial foam-based skin substitute scaffold of the present invention addresses the problems in the prior art by providing a biocompatible, biodegradable, Non-immunogenic, non-irritant and a cost-effective scaffold.

A polymer compound modified by an acryloyl derivative and a polythiol compound are used for preparing a thiol-modified polymer compound by a Michael addition reaction of thiol and conjugated double bonds. In addition to achieving the structural goal of the thiol-modified polymer compound, the preparation method further has the following advantages: flexibly and effectively controlling the structure and constitution of a synthetic product, and the types and contents of a large number of compound molecular functional groups; using reagents having high biocompatibility, and effectively controlling the production cost and reducing the toxicity in the synthesis process; and obtaining, under the conditions of using safety reagents and simple reaction steps, thiol-modified biocompatible polymer compounds that can be used as extracellular matrix materials and maintain good raw material structure and biological activity, with the types and contents of functional groups adjusted according to requirements, and meeting multiple clinical application requirements.

A surgical device includes a substrate and a first coating that covers at least a portion of the substrate. The first coating includes a first polymer. The first coating having antibiotics dispersed in the first polymer such that the first polymer releases the antibiotics as the first polymer degrades. A second coating covers at least a portion of the first coating. The second coating includes a second polymer. The second coating has ellagic acid dispersed in the second polymer such that the second polymer releases the ellagic acid as the second polymer degrades. In some embodiments, systems and methods are disclosed.

A surgical device includes a substrate and a first coating that covers at least a portion of the substrate. The first coating includes a first polymer. The first coating having antibiotics dispersed in the first polymer such that the first polymer releases the antibiotics as the first polymer degrades. A second coating covers at least a portion of the first coating. The second coating includes a second polymer. The second coating has ellagic acid dispersed in the second polymer such that the second polymer releases the ellagic acid as the second polymer degrades. In some embodiments, systems and methods are disclosed.